Zimmer Biomet to exclusively distribute genex in the U.S.

Zimmer Biomet will exclusively distribute genex Bone Graft Substitute in the U.S. orthopaedic market.

As part of the new agreement, genex has been upgraded to include a new closed-mixing system to shorten preparation time and extend working time. In additon, genex also includes a comprehensive set of delivery options to allow a surgeon to inject, mold or prepare beads in accordance with their chosen technique.

Michael Harris, Chief Executive Officer of Biocomposites, commented: “I’m delighted we are partnering with Zimmer Biomet to deliver our new genex Bone Graft Substitute product to the U.S. market. genex is already used and valued by surgeons in over 30 countries, including the US, undertaking 15,000 cases each year. The upgraded offering we are providing to Zimmer Biomet will benefit many more physicians and patients across the U.S. ”

Brian Hatcher, President of Zimmer Biomet’s CMFT, Foot & Ankle and Trauma: “We are excited to partner with Biocomposites to bring the new genex Bone Graft Substitute kits to surgeons as we continue to advance our mission to alleviate pain and improve the quality of life for people around the world.”

Closed-mixing system with comprehensive delivery options